ReviewAging and disease2024
The Double-Edged Effects of Substance P in the Pathology of Alzheimer's Disease.
Review in Aging and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuropeptides in the Management of Alzheimer's Disease: From Pathophysiology to Therapeutic Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is an irreversible neurodegenerative disease that manifests clinically as memory loss and so on. Neuroinflammation plays an important role in Alzheimer's disease. Meanwhile, widely distributed throughout the central nervous system, substance P exhibits important pro-inflammatory properties. The level of substance P is found to correlate with the course of Alzheimer's disease. Substance P can modulate the protein hydrolysis of amyloid precursor protein, the voltage-gated potassium channel, and the protein hydrolysis of this channel, exerting neuroprotective effects. At the same time, substance P can also exert damaging effects by mediating neuroinflammation, inhibiting cellular autophagy, activating mast cells, acting on leukocytes and altering blood-brain barrier permeability. Based on the complex manifestations of substance P in Alzheimer's disease, this review discusses both protective and damaging mechanisms, and plausible explanations for the double-edged effect of substance P, providing an outlook for future research focusing on substance P and Alzheimer's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.